Condensed Consolidated Statements of Operations - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Total revenue		$ 266,974	$ 83,177	$ 696,527
Operating costs and expenses
Research and development	$ 1,790,528	1,974,193	7,200,987	4,623,811
Research and Development - Milestone expense for Patagonia Pharmaceuticals LLC			4,000,000
Selling, general and administrative	1,336,668	1,296,641	4,551,406	3,918,042
Total operating expenses	3,127,196	3,270,834	15,752,393	8,541,853
Loss from operations	(3,127,196)	(3,003,860)	(15,669,216)	(7,845,326)
Other income (expense)
Interest expense	(71,203)		(167,531)
Other income			75,000
Forgiveness of PPP loan			37,772
(Loss) gain on foreign currency exchange	11,124	(1,544)	(32,690)	(541)
Total other income (expense)	(60,079)	(1,544)	(87,449)	(541)
Net loss	(3,187,275)	(3,005,404)	(15,756,665)	(7,845,867)
Dividends on Series A preferred stock		(36,685)		(108,858)
Net loss attributable to common stockholders	$ (3,187,275)	$ (3,042,089)	$ (15,756,665)	$ (7,954,725)
Basic net loss per share attributable to common stockholders	$ (1.52)	$ (4.15)	$ (10.16)	$ (11.09)
Diluted net loss per share attributable to common stockholders	$ (1.52)	$ (4.15)	$ (10.16)	$ (11.09)
Basic weighted average number of shares outstanding	2,095,091	733,194	1,550,326	717,476
Diluted weighted average number of shares outstanding	2,095,091	733,194	1,550,326	717,476
Grant revenue
Total revenue		$ 225,128	$ 83,177	$ 400,789
Milestone revenue
Total revenue		$ 41,846		$ 295,738